Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Zwipe AS – Last day of trading in subscription rights in rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ZWIPE AS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT. OSLO, NORWAY – 7 DECEMBER 2023 – Reference is made to the stock exchange announcement published by Zwipe AS (the "Company") on 30 November 2023,

Circio announces completion of planned safety review and opening for full enrollment of TG01 study at Oslo University Hospital

· Seven patients were enrolled in the safety cohort with follow-up for three months · TG01 was well tolerated, and no safety concerns were reported · The study is now open for full enrollmentOslo, Norway, 7 December 2023 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA and immunotherapy medicines, today announces that mutant RAS cancer vaccine TG01 adjuvanted by QS-21 STIMULON has passed the planned safety cohort review without any concerns in the multiple myeloma trial at Oslo University Hospital (OUS). The study has now opened for full

Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)

Lund, Sweden, 7 December 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in disease-related efficacy measures. Further analysis of efficacy data will be conducted in 2024. 15-HMedIdeS-09 is an open-label, single arm, trial evaluating the safety, tolerability and efficacy of imlifidase in GBS patients in combination with standard of care (SoC) intravenous immunoglobulin (IVIg).

The leading forum for public-private partnerships alongside COP returns for its 14th edition on 7–8 December at Conrad Dubai

7 DecemberConrad, Dubai, The United Arab Emirates   Gathering over 2000 decision-makers across business, finance institutions, governments and civil society, World Climate Summit – The Investment COP returns for its 14th year of top-tier discussions and collaboration on how to solve climate change, aligned with the COP28 Priorities.    As the largest C-level B2B-convening alongside COP, World Climate Summit facilitates the exchange of best practice and innovation across vital sectors crucial to decarbonisation efforts in the areas of energy, transport, buildings, industry,

The board of Smoltek Nanotech Holding AB (publ) has decided to carry out directed issues of shares and warrants of a total of approximately SEK 16 million

This press release is an English version of the previously published Swedish version, which has interpretive precedence. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. The board of Smoltek

HANZA AB (publ) successfully completes a directed new share issue of 3,529,412 shares and raises proceeds of approximately SEK 300 million

HANZA AB (publ) ("HANZA" or the "Company") has, in accordance with the Company's press release earlier today, completed an accelerated bookbuilding procedure and resolved on a directed new share issue of 3,529,412 shares at a subscription price of SEK 85 per share (the "Directed New Share Issue"). The subscription price for the shares in the Directed New Share Issue has been determined through an accelerated bookbuilding procedure carried out by Pareto Securities AB ("Pareto Securities” or the “Manager”). The Directed New Share Issue was several times oversubscribed, why the Company decided

Lundin Mining Announces TSX Approval for a Normal Course Issuer Bid

Vancouver, BC, December 6, 2023 /CNW/ - (TSX: LUN; Nasdaq Stockholm: LUMI) Lundin Mining Corporation (“Lundin Mining” or the “Company”) announces that the Toronto Stock Exchange (the “TSX”) has accepted the notice of Lundin Mining’s intention to renew its normal course issuer bid (the “NCIB”). The Company intends to continue to utilize the NCIB at its discretion to make opportunistic purchases to create shareholder value and manage the number of outstanding common shares of the Company (the “Common Shares”). This approval allows the Company to purchase up to 52,538,870 Common Shares,

ABS Publishes Industry-Leading Best Practices for ESG Reporting

New Report Complements ABS Sustainability Reporting Services (HOUSTON) With the increasing demand for environmental, social and governance (ESG) reporting in the maritime, offshore and oil and gas industries, many owners and operators are incorporating ESG criteria into their operations. The ABS ESG Blueprint is a new report that builds upon the work ABS is doing to support clients  in their sustainability reporting and assurance journeys.

Nordea Bank Abp: Repurchase of own shares on 06.12.2023

Nordea Bank AbpStock exchange release – Changes in company’s own shares06.12.2023 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 06.12.2023 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |0 |0.00 |0.00

Asetek A/S – Publication of Request to Delist Asetek's Shares From Oslo Børs

In continuation of Asetek A/S' ("Asetek") announcement on 8 March 2023 regarding Asetek's intention to list its shares on Nasdaq Copenhagen and subsequently apply for delisting of its shares on Oslo Børs, an extraordinary general meeting held on 5 December 2023 has resolved to approve an application for delisting of Asetek's shares on Oslo Børs. As such, Asetek has today submitted an application for delisting of Asetek's shares to Oslo Børs. Provided that Oslo Børs accepts the application, and subject to any further requirements from Oslo Børs, the delisting is expected to be completed

Smoltek Nanotech Holding AB (publ) intends to carry out a directed issue of shares and warrants of approximately SEK 14 million

This press release is an English version of the previously published Swedish version, which has interpretive precedence.  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. The board of Smoltek

Smoltek announces intention to sign a global exclusive license and services agreement for discrete and embedded capacitors with YAGEO Group

This press release is an English version of the previously published Swedish version, which has interpretive precedence. Smoltek Nanotech Holding AB (publ) (“Smoltek” or the “Company”) hereby announces its intention to enter into a license and services agreement (“the Agreement”) between its subsidiary Smoltek Semi AB (“Smoltek Semi”) and KEMET Electronics Corporation (“KEMET”), a subsidiary of YAGEO Group (“YAGEO”), a global electronic component company, which would grant YAGEO a global, exclusive right to manufacture and sell discrete and embedded capacitor products based on Smoltek's

Nordhealth AS: Results of Share Buy Back

Reference is made to the stock exchange announcement on 30 November 2023, where Nordhealth AS (the "Company") launched an offer to purchase up to 1,000,000 of its own shares through a reverse book building process (the "Offering"). The application period expired at 16:30 hours (CET) on 6 December 2023. Following the end of the application period, the Company has resolved to buy 992,624 shares at a price of NOK 23.00 per share, which equals approximately NOK 22.8 million in total. All offers to sell shares with limits at or below NOK 23.00 have been allocated in full. Allocation

Hemnet’s Buyer Barometer December 2023: Fewer buyers believe in decreasing property prices

In Hemnet’s Buyer Barometer for December, the proportion of buyers who believe that property prices will fall declined. Of the buyers surveyed, 31 percent said they believe prices will fall in the next six months. This is 7 percentage points lower than in November, when 38 percent believed in falling prices.   The proportion of buyers who believe property prices will rise has increased with 4 percentage points. From 20 percent in November to 23 now in December. Overall, this means a net difference (the difference between those who believe in increasing and decreasing prices) of -8

Vår Energi ASA’s share saving plan allocates shares

Sandnes, Norway, 6 December 2023: A total of 308 168 shares were purchased on behalf of employees in Vår Energi ASA (OSE: VAR) participating in the company’s employee share saving programme. The average purchase price was NOK 32.1133 per share. The transactions are based on savings made in October, November and December 2023. More than 80% of Vår Energi employees took part in the share saving plan for these months. As part of the programme, primary insiders in Vår Energi ASA (OSE: VAR) purchased 13 267 shares at an average price of NOK 32.1133 per share. Details on individual

HANZA AB (publ) explores conditions for carrying out a directed new share issue of approx. SEK 250 million

HANZA AB (publ) ("HANZA" or the "Company") intends to carry out a directed new share issue of approx. SEK 250 million to Swedish and international institutional, and other qualified investors, through an accelerated bookbuilding procedure (the “Directed New Share Issue”). HANZA has engaged Pareto Securities AB (the "Manager") to explore the conditions for carrying out the Directed New Share Issue.BackgroundThe company currently has a good financial position with a debt level well below the target that the interest-bearing net debt/adjusted EBITDA should amount to no more than 2.5.

#23-382 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

#23-381 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Compulsory Acquisition of Shares in Self Storage Group ASA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN CANADA, AUSTRALIA, NEW ZEALAND, SOUTH-AFRICA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Oslo, 6 December 2023 - Reference is made to the stock exchange announcement made on 30 November 2023 regarding settlement of the recommended voluntary offer (the “Offer”) by T-C Storage HoldCo AB (the “Offeror”) to acquire all of the issued and outstanding shares (the “Shares”) in Self Storage Group ASA (the “Company”, OSE: SSG) for NOK 40

Hamlet BioPharma’s continued development of brain tumor therapy

Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, shares an update today about the development of brain tumor therapy based on the investigational new drug Alpha1H. Hamlet BioPharma together with its partner Neurochase Ltd. are making progress with the early pre-clinical work for the treatment of brain tumors. Important milestones have been reached during the preclinical assessment.   Hamlet BioPharma is developing a new class of anti-cancer therapeutics for multiple cancer indications based on the

There are no items matching the current filter
There are no more items matching the current filter
Back to top